Navigation Links
Glaucoma Survey: Half Unaware of Preservative-Free Beta-Blocker, Ophthalmologists Cite Benefits of Preservative-Free Medications on Ocular Comfort and Quality of Life
Date:4/6/2009

LAWRENCEVILLE, N.J., April 6 /PRNewswire/ -- In a recent survey of ophthalmologists across the nation, virtually all (97%) believe preservative-free glaucoma medications can enhance the ocular comfort of glaucoma patients, while 86% believe that preservative-free glaucoma medications can enhance patient quality of life. Nine out of ten (89%) feel there are not enough preservative-free glaucoma medications available, and nearly half (47%) do not know a preservative-free beta-blocker is available.

The survey respondents acknowledged problems that can be caused by the preservatives in glaucoma medications, including ocular surface disease such as dry eye, and the impact of preservatives on medication tolerance and patient compliance. Three-quarters (73%) report the presence of preservatives does impact their decision-making process for a glaucoma therapy.

"Clinicians believe that the long term use of glaucoma medications with preservatives has been associated with ocular surface disease," explained William Trattler, M.D., Director of Cornea at the Center of Excellence in Eyecare in Miami and the survey author. "Clearly, more preservative-free glaucoma medication options are needed."

Problems Associated with Medication Preservatives

Three-quarters of the ophthalmologists surveyed (70%) report the preservatives in glaucoma medications are a significant cause of the ocular surface disease they see in glaucoma patients. Most believe each of the following is related to the preservatives in glaucoma medications: ocular surface disease (83%), conjunctival inflammation (75%), allergic reactions (71%) and dry eye (67%). Most believe that the ocular surface problems exacerbated by preserved glaucoma medications are a major cause of medication intolerance (67%) and poor compliance (62%).

Six out of ten of the ophthalmologists (60%) would prefer to prescribe glaucoma medications with no preservatives at all for their glaucoma patients with ocular surface disease or dry eye syndrome, compared to glaucoma medications preserved with BAK (3%) or non-BAK preservatives (36%).

Preservative-Free Beta-blocker

Nearly half (47%) do not know a preservative-free beta-blockers is available. TIMOPTIC(R) (timolol maleate ophthalmic solution) in OCUDOSE(R) (sterile ophthalmic unit dose dispenser) is the only preservative-free medication for glaucoma available in the U.S. The TIMOPTIC product line was recently acquired by Aton Pharma, Inc., which provides the dry eye medication LACRISERT(R) (hydroxypropyl cellulose ophthalmic insert), a preservative-free, once-daily*, patient-administered prescription insert indicated for moderate to severe dry eye.

"A preservative-free beta blocker is a consideration for many glaucoma patients, especially for those who already have dry eye or are at increased risk for ocular surface disease, such as the elderly, those on oral medications associated with dry eye and patients with existing lid margin disease," continued Dr. Trattler. "The use of a preservative-free glaucoma medication such as TIMOPTIC in OCUDOSE can help preserve the health of the ocular surface in glaucoma patients."

Survey Methodology

The survey, sponsored by Aton Pharma, was completed between March 24 and March 26, 2009. Ophthalmologists across the nation were invited via e-mail to enter the online survey, and those who treated 20 or more glaucoma patients per month were asked to complete the survey. A total of 124 completed the survey, including 36 glaucoma specialists and 40 cataract surgery specialists.

About TIMOPTIC(R) in OCUDOSE(R)

TIMOPTIC(R) (timolol maleate ophthalmic solution) in OCUDOSE(R) (sterile ophthalmic unit dose dispenser) is a preservative-free, non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Preservative-free TIMOPTIC is provided in OCUDOSE, a clear low density polyethylene unit dose container, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in two dosage strengths, 0.25 percent and 0.5 percent.

TIMOPTIC in OCUDOSE is contraindicated in patients with bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock; or hypersensitivity to any component of this product. Because of the potential effects of beta-adrenergic blocking agents on blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical ophthalmic administration.

About LACRISERT

LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. Most adverse reactions with LACRISERT were mild and transient and included transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, edema of the eyelids, and hyperemia. LACRISERT should not be used by patients who are hypersensitive to hydroxypropyl cellulose. If improperly placed, LACRISERT may result in corneal abrasion.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of ten products, with sales in over 30 countries, focuses on ophthalmic diseases, orphan conditions and acute care hospital products. For more information, see www.atonrx.com.

* Some patients may require the flexibility of twice-daily dosing for optimal results.


'/>"/>
SOURCE Aton Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Glaucoma surgery in the blink of an eye
3. Glaucoma surgery in the blink of an eye
4. Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings
5. Looking at Glaucoma as a Systemic Disease
6. Cost of glaucoma medications may impact treatment
7. January is National Glaucoma Awareness Month
8. Upcoming meeting will explore new technologies for glaucoma clinical drug trials
9. Dr. Welsh Self-Test Diagnoses Glaucoma, the Leading Cause of Preventable- Blindness
10. Mayor Bloomberg Declares March 6, 2008 World Glaucoma Day in New York City
11. Glaucoma May Boost Cardiovascular Death Risk in Blacks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. ... office is now offering a variety of comprehensive procedures for facial enhancement. The ... facial volume restoration, lip enhancement and nasal reshaping. , As a result, ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Ongoing news of ... Life Care Association™ (ALCA) to conduct a survey that takes a closer look at ... today illustrates the prevalence and causes of TBI among the aging population, and identifies ...
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit Advisors (UBA), ... latest addition to its growing list of Partner Firms. S.S. Nesbitt is ... Orlando to Huntsville and in between. , Harnessing the experience and insights of ...
(Date:2/10/2016)... ... 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company ... and full year ended December 31, 2015 on Monday, February 29, 2016 after the ... investment community following the release at 4:30 PM ET. Investors interested in participating by ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... time Emmy award winner and inspirational speaker Jan Fox will serve as keynote ... Speaking Boldly will provide participants with tools to more effectively communicate with their ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... ORLANDO, Fla. , Feb. 10, 2016 /PRNewswire/ ... of technologies and products that help uncover the ... and Swift Biosciences Inc., a developer of innovative ... collaboration and co-marketing partnership aimed at enabling translational ... few as a couple hundred tumor and normal ...
(Date:2/10/2016)... Fla. , Feb. 9, 2016  Until recently, ... were surgery or liposuction. Thankfully, the FDA approved the ... them to death. Coolsculpting was originally approved in 2010 ... the thighs and now the chin. With this add-on ... Center can use a smaller applicator, the CoolMini, to ...
(Date:2/10/2016)... India , February 10, 2016 ... The "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ... Trends, Technologies, Participants, and Environment" research report indicates ... worth over $149 billion by 2020 growing at ... up of companion diagnostics and targeted therapeutics and ...
Breaking Medicine Technology: